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Abstract
Matriptase-2 (MT-2) is a type II transmembrane serine protease and predominantly attached to the surface of hepatocytes. MT-2
decreases the production of hepcidin, a key regulator of iron homeostasis. In this study, the effects of four 3-
amidinophenylalanine-derived combined matriptase-1/matriptase-2 (MT-1/2) inhibitors (MI-432, MI-441, MI-460, and MI-
461) on hepcidin production were investigated in hepatocyte mono- and hepatocyte-Kupffer cell co-cultures. In MI-461-
treated cell cultures, the extracellular hydrogen peroxide contents and the interleukin-6 and -8 (IL-6 and IL-8) levels were
determined and compared to controls. Hepcidin overproduction was observed in hepatocytes upon treatment with MI-432,
MI-441 andMI-461 at 50 μM. In contrast, extracellular hydrogen peroxide levels were not elevated significantly after matriptase
inhibition with MI-461. Furthermore, MI-461 did not induce increases in IL-6 and IL-8 levels in these hepatic models. A model
of the binding mode of inhibitor MI-461 in complex with MT-2 revealed numerous polar contacts contributing to the nanomolar
potency of this compound. Based on the in vitro data on hepcidin regulation, treatment with MI-461 might be valuable in
pathological states of iron metabolism without causing excessive oxidative stress.
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Introduction
Hepcidin is mainly produced in the liver and acts as a key
regulator of iron homeostasis. It prevents excessive iron from
entering the blood circulation via inhibiting the absorption of
nutritional iron from enterocytes and suppressing the release
of iron. When the blood iron concentration is high, hepcidin
production in the liver becomes elevated and contrarily, in the
case of the iron shortage, the hormone secretion decreases
significantly leading to an enhanced iron transport (Ganz
and Nemeth 2012).
Thus, hepcidin prevents iron overload (Knutson et al.
2005) which could lead to the formation of reactive oxygen
species (ROS) or to severe damages to subcellular compo-
nents such as electron transport chain of respiration or mito-
chondrial DNA content. Furthermore, the rapid iron-lowering
ability of hepcidin seems to be a part of the conserved evolu-
tionary responses against pathogenic infections, which re-
stricts the access of bacteria to iron sources essential for their
further survival (Ganz and Nemeth 2012; Gao et al. 2009).
Hepcidin synthesis in the liver is upregulated by increasing
levels of plasma iron supported by the fact that iron-transferrin
saturation can stimulate transcription of the hepcidin encoding
hepcidin antimicrobial peptide (HAMP) gene.
In the case of anemia of inflammation or in the case of
prolonged conditions, anemia of chronic disease, macro-
phages do not release appropriate amount of iron into the
bloodstream due to the antiinfectious function of hepcidin
causing manifested systemic iron shortage (Ganz and
Nemeth 2012). Several studies were performed to establish a
relationship between hepcidin secretion and pathogen-
provoked inflammatory responses. Administration of lipo-
polysaccharide (LPS) could lead to elevation in hepcidin-
encoding mRNAs in hepatocytes and in mice (Pigeon et al.
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2001). Similar results were detected in mice exposed to
Candida albicans and in human hepatoma cell lines infected
with influenza A virus (Armitage et al. 2012). IL-6 seemed to
be a key mediator among pro-inflammatory cytokines in the
initiation for hepcidin overproduction in LPS-triggered in-
flammation, as application of IL-6 neutralizing antibodies
could significantly decrease the synthesis of hepcidin
mRNA. In accordance, IL-6 applied in infusions could en-
hance hepcidin amounts detected in human urine within few
hours (Nemeth et al. 2004).
Hepcidin level is reduced in hemolytic anemia and anemias
with ineffective erythropoesis. Hypoxia can trigger the eryth-
ropoiesis via erythropoietin (EPO) synthesis in kidney and
liver resulting in significant suppression of hepcidin; however,
the main factor in hepcidin regulation is the iron load of serum
transferrin, and not the effect of EPO (Piperno et al. 2011).
Hepatic oxidative stress as a consequence of excessive alcohol
consumption or viral infections can inhibit hepcidin produc-
tion and lead to iron overload which can further deteriorate the
already existing pathophysiological conditions (Fujita et al.
2007; Harrison-Findik 2007).
Type II transmembrane serine proteases (TTSPs) modulate
proteolytic processes on cell surfaces. The TTSPs can be di-
vided into four subfamilies, the matriptase, the hepsin/
TMPRSS, the corin, and the HAT/DESC family. All of these
proteases possess a cytoplasmic N-terminal segment, follow-
ed by a transmembrane domain, a middle multidomain-like
stem region of variable lengths, and a C-terminal trypsin-like
serine protease domain (Bugge et al. 2009). Matriptase-2
(MT-2 or TMPRSS6) similarly to matriptase-1 (MT-1) is
bound to cell membrane, and they are both capable of
degrading extracellular matrix (ECM) proteins. MT-2 is main-
ly found in human adult and embryonic liver.
Moreover, an extrahepatic occurrence of MT-2 encoding
mRNAs was detected in kidney and in uterine of mice (Hooper
et al. 2003). MT-2 takes part in the suppression of hepcidin
production via cleavage and decomposition of hemojuvelin
(HJV). In the liver, bone morphogenetic protein (BMP) pathway
acts as one of the key regulators for hepcidin transcription thus
for the iron metabolism. These findings were supported by the
fact that hepcidin responses to the acute and to the chronic iron
loading were impaired upon loss of these molecules (Babitt et al.
2006; Huang et al. 2005; Corradini et al. 2011). It was also
proven that the catalytic domain together with the stem region
of MT-2 is necessary for the effective inhibition of hepcidin
expression. TMPRSS6−/− mice have a dysfunctional MT-2 due
to a deficiency in the catalytic ectodomain, and it was observed
that iron deprivation itself did not induce elevated iron absorption
by enterocytes in mice with mutant MT-2 (Du et al. 2008).
TMPRSS6−/− mice with MT-2 deficiency suffered from
microcyter hypochrom anemia accompanied by alopecia, hair
follicular dystrophy, and hyperkeratosis. This condition could
be improved with parenteral iron-dextran treatment suggesting
the potential impact of MT-2 on iron homeostasis (Folgueras
et al. 2008). Accordingly, inhibition of MT-2 has been proposed
as a new therapeutic opportunity to treat iron overload diseases
(Sisay et al. 2010; Stirnberg and Gütschow 2013; Maurer et al.
2012).
In human patients and mice with iron-refractory iron defi-
ciency anemia (IRIDA), a genetic impairment of MT-2 was
observed to cause microcyter, hypochrom anemia with low
transferrin saturation (Finberg et al. 2008). Based on these
findings, it can be suggested that damage in the catalytic do-
main of MT-2 can affect adaptation ability when iron sources
in the body are lowered both in humans and in mice, and
excessive hepcidin synthesis can facilitate sequestration of
iron into macrophages and decreased iron absorption.
The positive and the negative regulators of the hepcidin pro-
duction and its effects on iron homeostasis are summarized in
Fig. 1. The extracellular trypsin-like serine protease domain at the
C-terminus of MT-1 and MT-2 can be inhibited by sulfonylated
3-amidinophenylalanine-derivatives, by various cyclic peptidic
inhibtors (Quimbar et al. 2013), short linear peptides with a C-
terminal arginylketonemoiety (Colombo et al. 2012) or dipeptide
derivatives containing C-terminal decarboxylated arginine mi-
metics (Sisay et al. 2010), or other zwitterionic amino acid de-
rivatives (Pászti-Gere et al. 2015) such as glyphosate, which is
likely to disrupt transferrin-based iron uptake (Samsel and Seneff
2016). Moreover, surfactant polyethoxylated tallow amines were
also found to inhibit matriptases possibly through membrane
disruption (Pászti-Gere et al. 2015). An inhibition of MT-1 and
MT-2 is also achieved by sulfonylated 3-amidinophenylalanine
derivatives (Hammami et al. 2012). The most potent analogues
of this inhibitor-type contain an N-terminal dichloro- or
dimethoxy-biphenyl-3-sulphonyl group and inhibit MT-1 in the
low one-digit nanomolar range, whereas the best inhibition con-
stants for MT-2 are close to 100 nM (Hammami et al. 2012;
Pomothy et al. 2016). However, the effects of these combined
MT-1/2 inhibitors on the compensation for iron homeostatic im-
balances caused by dysregulated hepcidin production have not
been elucidated yet.
A reliable mono- or co-culture model in an environment
which ensures appropriate cell adhesion and maintains cell-
cell contacts is needed to investigate the influence of drug
candidates in vitro and to predict their potential hepatic effects
in vivo. The assembly of hepatocytes into 3D structures con-
tributes to the maintenance of hepatocyte function to greater
extent over conventional monolayer cell systems. Hydrogel is
one of the support materials for the currently available 3D
environments offering an excellent basis for the development
of the desired 3D cell structure (Bachmann et al. 2015).
Recently, hydrogels have been widely used for pharmacolog-
ical investigations, toxicity, or controlled drug release studies
(Huh et al. 2011; Haycock 2010; Lee et al. 2008; Almany and
Seliktar 2005; Pongrácz and Bartis 2011; Bhattacharya et al.
2012; Khademhosseini and Langer 2007).
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The aim of our study was to screen the pharmacologi-
cal effects of 3-amidinophenylalanine-derived protease in-
hibitors on iron homeostasis via hepcidin modulation in
an in vitro hepatic model such as hepatocyte mono- and
hepatocyte-Kupffer co-cultures. After treatment with com-
pound MI-461, a profiling of its IL-6 and IL-8-regulating
and oxidative stress-inducing properties was performed to
elucidate and to predict the safety of this inhibitor. Special
emphasis was laid on evaluation and comparison of the
data obtained from 2D and hydrogel-assisted hepatic cell
mono- and co-cultures exposed to MT-1/2 inhibition.
Moreover, based on a previously described homology
model of MT-2 (Sisay et al. 2010; Maurer et al. 2012), a
reasonable binding mode of inhibitor MI-461 within its
active site was predicted.
Materials and methods
Isolation and cultivation of hepatocytes and Kupffer
cells
Hepatocytes and hepatocyte-Kupffer cell co-cultures
were freshly prepared from 15 kg weighing male pigs
of the Hungarian Large White breed (obtained from
Dunahyb Ltd, Fadd, Hungary) (Mátis et al. 2016).
Hepatocytes and Kupffer cells were isolated by multi-
step perfusion and collagenase-mediated enzymatic di-
gestion of the caudate lobe of the liver. All animal
experiments were carried out in accordance with the eth-
ical guidelines for the care and use of laboratory animals.
The study was authorized by the Animal Welfare
Committee of the University of Veterinary Medicine in
Budapest, Hungary. Hepatocytes were sedimented and
purified by a revised low-speed centrifugation (50×g,
75 s), and Kupffer cells were obtained from the superna-
tants by Percoll gradient centrifugation (500×g, 20 min).
As non-parenchymal cells can attach faster, Kupffer cells
were seeded first on previously collagen-coated (Type I,
10 μg/cm2) 12-well Costar TC6 cell culture dishes
(Corning International, Corning, NY, USA) and on 96-
well microplates, the latter used for MTS assays on cell
viability. Hepatocytes in mono-cultures (Hep) or hepato-
cytes and Kupffer cells (HepK) were seeded in cell ratio
6:1 (hepatocyte to Kupffer cell). The prepared mono- or
co-cultures were incubated under humid atmosphere at
37 °C using 10% CO2, and culture medium was ex-
changed 6 h after seeding. Culturing of cells was per-
formed in Williams’ Medium E, supplemented with
penicillin–streptomycin (1%), glutamine (2 mM), FBS
(5%), and insulin (20 IU/ml). Fetal bovine serum (FBS)
was applied during the first 24 h of culturing. Confluent
mono- and co-cultures suitable for the further examina-
tions were obtained after 24-h incubation. Cell lysate
protein content was spectrophotometrically determined
with Bio-Rad Bradford protein assay (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) at 595 nm with
bovine serum albumin as a standard.
Hepcidin synthesis
Inflammatory 
cytokines 
(IL-6)
Oxidave 
stress
Erythropoiesis
(EPO)
Serum iron level
ferroporn
enterocytes hepatocytes
macrophage
+
Transferrin 
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Mask mutaon 
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+
Fig. 1 The iron level in the blood
is dependent on hepcidin
production maintained by
positive regulators, like
transferrin saturation, interleukin-
6 (IL-6), and defective matriptase-
2 (MT-2) (green boxes) and neg-
ative regulators such as erythro-
poietin (EPO), and oxidative
stress (light red boxes). The iron
homeostatic processes involve
interplay between macrophages,
hepatocytes, and intestinal epi-
thelial cells. Stimulatory effects in
hepcidin synthesis are indicated
with + and the inhibitory factors
of the production is labelled with
− sign. Increased hepcidin levels
result in reduced serum iron levels
due to the inhibition of
ferroportin, and vica versa
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Hydrogel-based cell culturing
Lyophilized HydroMatrix (Sigma-Aldrich, Saint Luis,
Montana, USA) was used at 0.25% concentration for hy-
drogel preparation. Hepatocytes and Kupffer cells were
added to the hydrogel-assisted matrices at the physiolog-
ical pH. The culturing of Hep and HepK cells was carried
out in Williams’ E medium on hydrogel-covered 6-well
polyester membrane inserts (Costar Transwell, surface ar-
ea 4.67 cm2/well).
Exposure of Hep and HepK6 cells to matriptase
inhibitors
Ten mM stock solutions of the inhibitors (MI-432, MI-441,
MI-460, and MI-461) (Fig. 2) were kept at − 20 °C. Before
treatment, confluent Hep and HepK6 co-cultures were washed
twice with plain medium.
The solutions of the inhibitors in phenol red free
Williams’ Medium E at 50 μM (in the case of MI-461,
1, 10, 30, and 50 μM) were prepared freshly prior to each
experiment from the stock solutions. It was found that the
selected inhibitors can be used at 50 μM concentration
safely for 24 h (cell death rate was less than 5% in con-
trols and in treated samples) in Hep mono- and HepK6
co-cultures (Pomothy et al. 2016) using MTS assay and
this concentration could be applied in further experiments
to characterize the effects of MT-1/MT-2 modulation in
our hepatic models for 24 h. After incubation with the
inhibitors for 24 h, the mono- and co-cultures were
washed twice with plain medium before being subjected
to the subsequent procedures.
Hepcidin ELISA measurements
Porcine ELISA kit for hepcidin analysis was obtained from
Cloud-Clone Corp. (Houston, Texas, USA). Hepcidin calibra-
tion curve was prepared using hepcidin standard solutions in
different concentrations (0 pg/ml, 740 pg/ml, 2222 pg/ml,
6667 pg/ml, 20,000 pg/ml). The equation of calibration curve
was the following:
Absorbance = 0.000318725 × concentrationhepcidin (pg/ml)
+ 0.0011 with R2 = 0.9963.
After 24-h lasting inhibitor treatment of the Hep and
HepK6 (50 μM MI-432, MI-441, MI-460, and MI-461),
the culture media from 2D and hydrogel-assisted cell
matrices were collected, centrifuged (1000×g for 20
min) and diluted in PBS. For detailed elucidation of
the concentration-dependent effect of MI-461 adminis-
tration on hepcidin levels, 0, 1, 10, 30, and 50 μM
MI-461 solutions were also added to Hep. Cell cultures
were also exposed to LPS after 24-h cultivation to mon-
itor changes in hepcidin production. The cells were
incubated with LPS derived from Salmonella enterica
ser. Typhimurium (1 μg/ml) (obtained from Sigma-
Aldrich, Germany) for 1 h. The assay procedure was
performed according to the manufacturer’s guideline.
After addition of the 3,3′,5,5′-tetramethylbenzidine
(TMB) substrate solution for 15 min, the intensity of
color developed is reverse proportional to the concentra-
tion of hepcidin in the sample. The absorbance values
were detected at 450 nm using an EZ Read Biochrom
400 microplate reader (Biochrom Ltd, UK) and normal-
ized to protein content of the samples.
MI-432
MI-441
MI-460
MI-461
Fig. 2 Structures of the 3-amidinophenylalanine-derived MT-1/2 inhibi-
tors (Hammami et al. 2012) used in this study
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Extracellular H2O2 measurement by the Amplex red
method
Fluorescence ROSmeasurement of cell supernatant was based
on the detection of H2O2 using the Amplex Red Hydrogen
Peroxide Assay Kit (Invitrogen, Molecular Probes). To deter-
mine in which concentration range the assay can be used in
quantitative manner, calibration curve was prepared using
H2O2 solutions in different concentrations (0 μM, 0.315
μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM). The equation of
calibration curve was found as follows:
Fluorescence intensity = 9945.7 × concentrationH2O2 (μM)
+ 5135.8 with R2 = 0.9972.
Following the exposure of mono- and co-cultures to MI-
461 (50 μM, 24 h), the H2O2 concentrations in the medium
were determined using a working solution of 100 μMAmplex
Red and 0.2 U/ml HRP. After 30-min incubation with the dye
at room temperature, the quantitative H2O2 contents were
measured using a Victor X2 2030 fluorometer (λex = 560
nm, λem = 590 nm).
IL-6 and IL-8 determination by enzyme-linked
immunosorbent assays
Previous characterization of LPS-induced changes in levels of
pro-inflammatory cytokines such as quantitative analyses of
IL-6 and IL-8 production in Hep mono- or HepK6 co-cultures
model systems was performed, and data have already been
published by Mátis et al. (2016). It was ascertained that LPS
challenge of porcine Hep and HepK6 resulted in increased IL-
6 and IL-8 levels in cell supernatants. After 24-h long inhibitor
treatment (50 μM,MI-461), Hep mono- or HepK6 co-cultures
were incubated in the medium for 24 h. Culture media were
collected, centrifuged (245×g for 10 min), and diluted to mea-
sure IL-6 or IL-8 levels. Changes in IL-6 or IL-8 levels were
determined by porcine-specific IL-6 (Sigma-Aldrich, St
Louis, MO, USA) or by porcine-specific IL-8 (Invitrogen
Corporation, Waltham, MA, USA) ELISA kits according to
the manufacturer’s instructions. The absorbance values were
detected at 450 nm using an EZ Read Biochrom 400 micro-
plate reader (Biochrom Ltd, UK) and normalized to protein
content of the samples.
Model of matriptase-2 in complex with inhibitor
MI-461
The coordinates of the previously described homology model
of MT-2 (Sisay et al. 2010) were superimposed with the crys-
tal structure of thrombin in complex with inhibitor MI-432
(PDB: 4e7r) (Hammami et al. 2012) followed by the deletion
of thrombin. The C-terminal amine of inhibitor MI-432 was
converted into a methylurea group present in analogue MI-
461 using the builder function implemented in MOE
(Molecular Operating Environment (MOE), 2013.08;
Chemical Computing Group Inc., 1010 Sherbooke St. West,
Suite #910, Montreal, QC, Canada, H3A 2R7) followed by an
energy minimization of the inhibitor within the active site of
MT-2. The minimization was performed with the MMFF94
forcefield implemented in MOE using the default parameters,
whereas the structure of MT-2 was kept constant.
Statistical analysis
For statistical evaluation, R 2.11.1 software package (2010)
was applied. Differences between absolute means were eval-
uated by one-way analysis of variance (one-way ANOVA)
with post hoc Tukey test, where data were of normal distribu-
tion and homogeneity of variances was confirmed.
Differences were considered significant if the p value was <
0.05 marked with * (***p < 0.001).
Results
Effects on hepcidin secretion
Hep mono- and HepK6 co-cultures embedded in the presence
or absence of hydrogel matrices were exposed to 50μMof the
dual MT-1/2 inhibitors (MI-432, MI-441, MI-460, and MI-
461) for 24 h, and the data were compared to untreated sam-
ples (Fig. 3). In hepatocyte 2D and hydrogel-based hepatocyte
3D cultures, MI-432, MI-441, and MI-461 caused significant
elevations in hepcidin secretion (p < 0.001) (Fig. 3a and b). In
contrast, no significant changes were observed in hepcidin
levels in 2D and hydrogel-assisted hepatocyte-Kupffer cell
co-cultures exposed to the MT-1/2 inhibitors (p > 0.05) (Fig.
3c and d). It was also found that LPS at 1 μg/ml used as
positive control could significantly elevate hepcidin produc-
tion (p < 0.001). Among the tested matriptase inhibitors, only
MI-461 could increase hepcidin production in vitro at 30 μM
(p = 0.022) and 50 μM (p < 0.001); thus, this compound was
selected for further investigations in our study (Fig. 4).
Lack of changes in extracellular hydrogen peroxide
production after MI-461 administration
After 24-h exposition of hydrogel-based hepatocyte mono-
cultures and hepatocyte-Kupffer-cell co-cultures to 50 μM
MI-461, the fluorescence intensities of Amplex red were de-
tected. No significant changes were seen in the extracelullar
ROS levels in the supernatants of mono-cultures (p = 0.197) in
the control andMI-461-treated samples. Administration of the
protease inhibitor did not alter significantly the extracellular
hydrogen peroxide production of the inflammatory co-culture
model (p = 0.905) (Fig. 5).
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IL-6 and IL-8 cytokine profiles of hepatocytes
and hepatocyte-Kupffer cell co-cultures
IL-6 levels were not significantly altered when hepatocyte
mono-cultures (Fig. 6a) and co-cultures (Fig. 6b) were
Fig. 3 Determination of hepcidin levels of 2D and hydrogel-based hepa-
tocyte mono- and hepatocyte-Kupffer cell co-cultures (ratio 6:1) treated
with one of the four different MT-1/2 inhibitors (MI-432, MI-441, MI-
460, MI-461) at 50 μM for 24 h (control in absence of inhibitors). Data
are shown as average absorbance values ± SEMs (n = 4). a An increase
was found in the hepcidin levels between treated and control 2D
hepatocyte samples (p < 0.001) except in the case of samples exposed
to MI-460 (p > 0.05). b Significant changes were found in the hydrogel-
assisted mono-culture after MT-1/2 inhibition with MI-432, MI-441, and
MI-461 (p < 0.001). c, d Treatment of 2D and 3D hepatocyte-Kupffer cell
co-cultures with inhibitors did not result in significant increases in
hepcidin production (each case p > 0.05)
0
0,2
0,4
0,6
0,8
1
1,2
1,4
LPS untreated MI-461   
1 µM
MI-461 
10 µM
MI-461 
30 µM
MI-461 
50 µM
ecnabrosb
A
*** 
*
***
Fig. 4 Analysis of MI-461-induced hepcidin overproduction in 3D
hepatocyte samples. MI-461 was used at different concentrations (0
μM, 1 μM, 10 μM, 30 μM, and 50 μM) to elucidate concentration-
dependent effect of matriptase inhibition on changes in hepcidin
levels. LPS at 1 μg/ml was used as positive control (p < 0.001).
MI-461 at 30 μM and 50 μM could induce hepcidin secretion signif-
icantly (p = 0.022 and p < 0.001, respectively). Data are shown as
average absorbances ± SDs (n = 5)
0
5000
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15000
Control MI-461
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Fig. 5 Determination of extracellular H2O2 levels by the Amplex red
method after 24-h long treatment with 50 μM MI-461 on 3D mono-
and co-cultures. Data are shown as average fluorescence intensities ±
SDs (n = 3). Treatment did not cause significant differences in the hydro-
gen peroxide production of applied hepatic cell cultures (p > 0.05)
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exposed to MI-461 for 24 h in hydrogel-free (p = 0.998 in
mono-cultures, p = 0.786 in co-cultures) and hydrogel-
assisted systems (p = 0.934 in mono-cultures, p = 0.991 in
co-cultures). The IL-8 levels did not change significantly after
24-h-long 50 μMMI-461 administration in hepatocytes inde-
pendently of the presence of hydrogel-base (Fig. 6c in 2D, p =
0.053; and in hydrogel, p = 0.317). In hepatocyte-Kupffer co-
culture system (Fig. 6d), IL-8 levels were slightly elevated
compared to those in hepatocytes. No anti-inflammatory ef-
fect of MI-461 was detected (p = 0.051) in the hydrogel-
assisted co-culture system and in co-cultures without using
hydrogel (p = 0.823).
Molecular modeling of the interaction between MT-2
and MI-461
When bound to the active site of MT-2, the inhibitor MI-461
adopts a very similar overall conformation as observed for re-
lated sulfonylated 3-amidinophenylalanine-piperidide deriva-
tives in complex with various trypsin-like serine proteases such
as thrombin (Bergner et al. 1995), trypsin (Renatus et al. 1998),
urokinase-type plasminogen activator (Zeslawska et al. 2000),
or matriptase (Steinmetzer et al. 2006). The amidine group
interacts with Asp189 at the bottom of the S1 pocket and forms
an additional H-bond to the carbonyl oxygen of Gly219. The
backbone of the P1 residues makes an antiparallel β-sheet
interaction to the NH and carbonyl of Gly216, and an additional
H-bond is formed between one sulfonyl oxygen and the NH of
Gly219. The N-terminal dichloro-substituted phenyl ring is ac-
commodated in the distal S3/4 pocket above Trp215, which is
surrounded byHis99 on the right, but otherwise, relatively open
on the left side close to Gln174. The piperidide is located in a
region below His57 and His99, which is normally occupied by
the side chain of the P2 residue in substrate-analogue structures.
No specific interaction could be found for the C-terminal
methylurea group (Fig. 7).
Discussion
Recently, first hepcidin agonists for the treatment of iron over-
load have been described based on small peptidic hepcidin
analogs. Moreover, analogs of BMP6, a protein which in-
creases hepcidin expression in vivo (Andriopoulos et al.
2009), and antisense oligonucleotides targeting MT-2 activity
have been developed to enhance hepcidin activities (Ganz
2013). It is worth to note that the therapeutical oral application
of Mesupron, an anti-metastatic and structurally closely relat-
ed 3-hydroxyamidinophenylalanine-prodrug of the active in-
hibitor WX-UKI-1, seems to be safe and effective in cancer
treatment. WX-UKI-1 was originally described as inhibitor of
the urokinase-type plasminogen activator (uPA) (Stürzebecher
0
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Fig. 6 Determination of IL-6 and IL-8 levels of 2D and 3D (hydrogel-
assisted) hepatocyte mono- (a, c) and hepatocyte-Kupffer cell co-cultures
(ratio 6:1) (b, d) withoutMT-1/2 inhibition or treated with 50μMMI-461
for 24 h. Data are shown as average absorbance values ± SEMs (n = 3).
No significant changes were found in the IL-6 and IL-8 levels in mono-
cultures and co-cultures between treated and control samples in the ab-
sence and in the presence of hydrogel-assisted matrices (p > 0.05). There
was significant increase in IL-6 levels in supernatants of co-cultures com-
pared to those produced in hepatocytes (p < 0.001) without matriptase
inhibition. Regarding the cells not exposed to MI-461 treatment, no sig-
nificant differences were found in IL-8 production between hepatocyte
mono- and hepatocyte-Kupffer cell co-cultures (ratio 6:1) (p > 0.05)
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et al. 1999), but also inhibits MT-1 with similar potency (Ki
values for uPA 0.65 μM and for MT-1 0.37 μM, respectively).
Based on our in vitro findings with hepatocytes in con-
ventional 2D environment and hydrogel-assisted matrices,
it can be reported that the applied 3-amidinophenylalanine-
derived dual MT-1/2 inhibitors (MI-432, MI-441, and MI-
461) at 50 μM for 24 h lead to a significant elevation of
plasma hepcidin concentrations. The application of these
agents might be of therapeutical importance in such dis-
eases where too low hepcidin levels are not able to prevent
excessive iron release from enterocytes, macrophages, and
hepatocytes and to protect tissues from the negative con-
sequences of iron overload.
One of these disorders is hereditary hemochromatosis,
which can be formed when hepcidin expression is dis-
turbed via mutations in the hepcidin gene itself or in the
genes encoding hepcidin regulators leading to iron depo-
sition in tissues and iron-mediated organ dysfunctions.
Mutations in the genes of hepcidin or HJV can be the
cause for the development of juvenile form of this disease
which develops fast, and it is accompanied by severe
damages including cardyomyopathy and endocrinopathies
(Pietrangelo 2010; Nemeth and Ganz 2009). The hepato-
cyte mono- and the hepatocyte-Kupffer cell co-culture in
2D environment and embedded in a hydrogel-based 3D
structures provide an excellent model system for studying
the in vitro effects of synthetic protease inhibitors.
Porcine hepatocyte-Kupffer co-cultures were previously
used for mimicking hepatic inflammation, for studying
LPS-induced inflammatory responses and for screening
beneficial effects of potential anti-inflammatory agents
(Mátis et al. 2016). Noteworthy, discrepancies between
the effects of the selected MT-1/2 inhibitors on hepcidin
productions in hepatic mono- and co-cultures may suggest
different mode of actions of dual MT-1/MT-2 inhibition in
the case of pathophysiological conditions.
The biochemical characterization of the matriptase inhibi-
tor MI-461 containing an N-terminal dichlorobiphenyl-3-
sulfonyl group revealed that this compound did not perturbate
the redox state of Hep and HepK6 cultures based on the data
from extracellular hydrogen peroxide measurements when it
was used at 50 μM concentration for 24 h. It was also
ascertained that MI-461 did not increase the levels of two
proinflammatory cytokines, IL-6 and IL-8 levels; thus, the
application of MI-461 did not provoke inflammatory re-
sponses in hepatocytes and hepatocyte-Kupffer cell co-
culture systems. The administration of more efficient MT-2
inhibitors might present a novel drug alternative to prevent
the excessive release of inflammatory mediators and hepatic
dysfunction characteristic of iron overload in Kupffer cells
(Jomova and Valko 2011; She et al. 2002).
In conclusion, our in vitro pharmacological investiga-
tions revealed that combined MT-1/2 inhibition itself does
not induce oxidative stress, and it can exert beneficial
effects on restoration of tipped iron metabolism via regu-
lation of hepcidin production. The different findings
Fig. 7 Modeled structure of inhibitor MI-461 in complex with MT-2
indicating polar interactions as dashed lines in black. Important MT-2
residues are labeled based on the chymotrypsinogen numbering. a MT-
2 is shown with its solvent exposed transparent surface colored in beige,
the inhibitor is shown as stick model with carbon atoms in white.
ImportantMT-2 residues in the active site are given as sticks with carbons
in yellow (oxygen in red, nitrogen in blue, sulfur in yellow, and chlorine
in green). b View on the active site of MT-2 indicating polar interactions
of MI-461 with residues Asp189, Gly219, and Gly216. The figures were
prepared using PyMOL v0.98 (DeLano Scientific, San Carlos, CA)
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between measurements performed on monolayer or on
hydrogel matrices require further experiments, for exam-
ple, by applying hepatocye-Kupffer cell co-culture with
different cell ratios or by employing various 3D cultiva-
tion methods to investigate matriptase inhibitor-caused
pharmaco-toxicological effects in-depth.
It is widely accepted that MT-2 can reduce hepcidin con-
centrations via cleavage of hemojuvelin. Inhibition of MT-2
leads to reduced hemojuvelin cleavage (and to higher hepcidin
levels) resulting in lower iron concentration in blood. No pa-
pers have been published yet which at least assume that
hemojuvelin cleavage can be accomplished via thrombin, fac-
tor Xa, and MT-1. However, with a Ki value of 0.073 μM
inhibitor, MI-461 is only a moderately active MT-2 inhibitor
and is still a relatively non-selective compound because it also
inhibits MT-1 and other trypsin-like serine proteases.
Therefore, the development of more potent and ideally also
selective MT-2 inhibitors is required in the future. The model
of inhibitor MI-461 in complex with MT-2, indicating several
polar contacts which contribute to the submicromolar potency
of this 3-amidinophenylalanine derivative, reveals that this
inhibitor type is a suitable start structure for further lead
optimization.
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